Parallax Volatility Advisers, L.P. Nektar Therapeutics Call Options Transaction History

Parallax Volatility Advisers, L.P.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $24,092 - $46,892	-7,600 Reduced 36.02%	13,500 $51,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $2,080 - $6,860	500 Added 2.43%	21,100 $114,000
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $269,242 - $388,104	20,600 New	20,600 $370,000
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $406,477 - $585,924	-31,100 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $503,860 - $622,200	30,500 Added 5083.33%	31,100 $534,000

Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $3.41 Million - $6.34 Million	-111,900 Reduced 99.47%	600 $20,000
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $8.69 Million - $12.8 Million	-187,000 Reduced 62.44%	112,500 $6.86 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $11.8 Million - $26.6 Million	254,500 Added 565.56%	299,500 $14.6 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $1.04 Million - $2.72 Million	45,000	45,000 $2.69 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.